Corporate Presentations

Q2 2023 Investor Presentation
Q2 2023 Investor Presentation

Published: August 16, 2023

Other Presentations

Direct Lytic Agents to Combat Antimicrobial Resistance
Direct Lytic Agents to Combat Antimicrobial Resistance

Published: September 7, 2023
Single Center, Exploratory, Open-Label Prospective Study Using the Minimally Invasive LysinDAIR Procedure in Patients with Chronic Coagulase-Negative Staphylococci Knee PJI with Two Different Clinical Presentations and Treatment Paradigms
Single Center, Exploratory, Open-Label Prospective Study Using the Minimally Invasive LysinDAIR Procedure in Patients with Chronic Coagulase-Negative Staphylococci Knee PJI with Two Different Clinical Presentations and Treatment Paradigms

Published: September 8, 2022
In Vivo Efficacy of CF-370 Alone and in Addition to Amikacin in the Rabbit Acute Pneumonia Model Caused by Extensively Drug-resistant (XDR) Pseudomonas aeruginosa
In Vivo Efficacy of CF-370 Alone and in Addition to Amikacin in the Rabbit Acute Pneumonia Model Caused by Extensively Drug-resistant (XDR) Pseudomonas aeruginosa

Published: April 26, 2022
Lysin CF-370 Exhibits Potent Bactericidal Activity Against Clinical MDR and XDR Pseudomonas aeruginosa Isolates Including Carbapenem and/or Colistin Resistant Forms
Lysin CF-370 Exhibits Potent Bactericidal Activity Against Clinical MDR and XDR Pseudomonas aeruginosa Isolates Including Carbapenem and/or Colistin Resistant Forms

Published: July 19, 2021
Synergistic anti-biofilm activity of exebacase and rifampin, vancomycin or daptomycin against Staphylococcus epidermidis strains responsible for bone and joint infections
Synergistic anti-biofilm activity of exebacase and rifampin, vancomycin or daptomycin against Staphylococcus epidermidis strains responsible for bone and joint infections

Published: July 19, 2021
Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens
Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens

Published: July 19, 2021
Exebacase Reduced Length of Stay and 30-Day Readmission Rates for US Patients with MRSA Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics Alone in a Phase 2 Study
Exebacase Reduced Length of Stay and 30-Day Readmission Rates for US Patients with MRSA Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics Alone in a Phase 2 Study

Published: October 3, 2019
PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase(CF-301) in Pre-Clinical Models<br>ASM 2019, Outstanding Abstract Award
PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase(CF-301) in Pre-Clinical Models
ASM 2019, Outstanding Abstract Award

Published: June 22, 2019
Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics (SOC) Alone In A First-in-Patient Phase 2 Study
Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics (SOC) Alone In A First-in-Patient Phase 2 Study

Published: April 16, 2019
Direct Lytic Agents: differentiated, first-in-class biologics for the treatment of life-threatening and drug-resistant infections
Direct Lytic Agents: differentiated, first-in-class biologics for the treatment of life-threatening and drug-resistant infections

Published: April 14, 2019
Bacteriophage-Derived Lysins Exert a Potent Bactericidal Effect Against <em>Pseudomonas aeruginosa</em>
Bacteriophage-Derived Lysins Exert a Potent Bactericidal Effect Against Pseudomonas aeruginosa

Published: February 26, 2019
Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis
Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis